iShares Biotechnology ETF $IBB Stock Purchased by NTV Asset Management LLC

NTV Asset Management LLC boosted its stake in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 4.8% during the 3rd quarter, Holdings Channel.com reports. The firm owned 67,028 shares of the financial services provider’s stock after acquiring an additional 3,043 shares during the period. iShares Biotechnology ETF accounts for approximately 1.3% of NTV Asset Management LLC’s portfolio, making the stock its 13th biggest position. NTV Asset Management LLC’s holdings in iShares Biotechnology ETF were worth $14,111,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the stock. Bank of America Corp DE raised its position in iShares Biotechnology ETF by 10.8% in the 1st quarter. Bank of America Corp DE now owns 7,259,501 shares of the financial services provider’s stock valued at $1,225,767,000 after purchasing an additional 707,343 shares in the last quarter. Royal Bank of Canada boosted its stake in shares of iShares Biotechnology ETF by 1.0% in the 1st quarter. Royal Bank of Canada now owns 737,128 shares of the financial services provider’s stock valued at $124,464,000 after buying an additional 7,434 shares during the period. Janney Montgomery Scott LLC boosted its stake in shares of iShares Biotechnology ETF by 5.4% in the 1st quarter. Janney Montgomery Scott LLC now owns 652,818 shares of the financial services provider’s stock valued at $110,228,000 after buying an additional 33,268 shares during the period. Cetera Investment Advisers grew its position in shares of iShares Biotechnology ETF by 9.4% during the first quarter. Cetera Investment Advisers now owns 128,530 shares of the financial services provider’s stock worth $21,702,000 after buying an additional 10,994 shares in the last quarter. Finally, Albion Financial Group UT grew its position in shares of iShares Biotechnology ETF by 1.0% during the third quarter. Albion Financial Group UT now owns 120,782 shares of the financial services provider’s stock worth $25,428,000 after buying an additional 1,147 shares in the last quarter. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Price Performance

Shares of iShares Biotechnology ETF stock opened at $207.74 on Friday. The business has a 50-day simple moving average of $207.88 and a 200-day simple moving average of $189.30. iShares Biotechnology ETF has a one year low of $154.62 and a one year high of $217.12.

iShares Biotechnology ETF Cuts Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, September 18th. Investors of record on Tuesday, September 15th were paid a $0.0112 dividend. This is a decrease from iShares Biotechnology ETF’s previous quarterly dividend of $0.0238. This represents a $0.04 dividend on an annualized basis and a yield of 0.0%. The ex-dividend date was Tuesday, September 15th.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.